Neurohormonal dysfunction (increased sympathetic nervous system and renin angiotensin-aldosterone system) play an important role in pulmonary hypertension progression.
SUMMARY
Neurohormonal overactivation plays an important role in pulmonary hypertension (PH). In this context, renal denervation, which aims to inhibit the neurohormonal systems, may be a promising adjunct therapy in PH. In this proof-of-concept study, we have demonstrated in 2 experimental models of PH that renal denervation delayed disease progression, reduced pulmonary vascular remodeling, lowered right ventricular afterload, and (1, 2) .
Neurohormonal mediators, such as the sympathetic nervous system (SNS) and renin angiotensinaldosterone system (RAAS) are involved in the progression of PH and may contribute to pulmonary vascular remodeling and RV dysfunction (3) (4) (5) (6) . Increased levels of SNS activity have been reported in PH patients (7, 8) and are associated with disease progression and prognosis (9) . Previously reported evidence by our group and others showed that systemic (10) and local (11) RAAS activities are increased in PH patients and are also associated with disease progression (4) . Additionally, we demonstrated that chronic angiotensin II type 1 (AT1)-receptor blocker treatment delayed disease progression, reduced pulmonary vascular remodeling, and improved RV diastolic function in a PH animal model (4) . Furthermore, previous studies in experimental PH provided evidence that modulation of the sympathetic system improved RV systolic function (12, 13) and pulmonary vascular remodeling (12, 14) . Therefore, targeting the RAAS and SNS could be a promising therapy in PH (1, 3, 5) .
In this context, renal denervation (RD) might be pertinent. RD aims to abolish afferent and efferent renal nerve signaling (15) (16) (17) . Afferent renal nerve activation is sympathoexcitatory (18, 19) , whereas renal efferent nerve activation results in vasoconstriction, sodium retention, release of renin from the juxtaglomerular cells, and contributes to angiotensin II and aldosterone production (20, 21) , both of which exacerbate PH. In the present study, we investigate the effect of RD treatment on pulmonary vascular remodeling and cardiac function in 2 well-established PH animal models (4, 22, 23) .
METHODS

All experiments were approved by the Institutional
Animal Care and Use Committee of the VU University, Amsterdam, the Netherlands (FYS 13-05 and and performed according to the Declaration of Helsinki conventions for the use and care of animals.
EXPERIMENTAL PH. In this study we investigated the effects of RD-therapy in 2 PH animal models: were cut under a dissection microscope (25X) and the vessels were coated with a solution of 10% phenol in ethanol (24) . In the sham group, the same surgical procedure was performed, but renal nerves remained intact and no phenol solution was used. Tables 1 and 2) , whereas no effect in heart rate or in RV end-systolic pressure were observed after RD treatment ( Tables 1 and 2 ). Other than the hypotensive effect of RD therapy, no macroscopic kidney damage, kidney mass ( Supplemental Tables S1   and S2 ), or signs of animal discomfort were observed.
Before surgery was performed, PH development in ( Tables 1 and 2) . Although not statistically significant, we observed a minor reduction in RV contractility Values are mean AE SEM. One-way ANOVA followed by Bonferroni correction.
SuHx ¼ sugen þ hypoxia; other abbreviations as in Table 1 . Histological analyses from the relative wall thickness of pulmonary arterioles indicated a significant reduction in media wall thickness in both models ( Figures 4C and 4D) , and reduced intima wall thickness in the SuHx model ( Figure 4E) . Moreover, RD treatment decreased the formation of occlusive vascular lesions in both PH models ( Figures 4F and 4G ).
RV cardiomyocyte CSA was significantly reduced in both models due to RD ( Figure 5) ; however, no effect on LV cardiomyocyte CSA was observed ( Supplemental   Tables S1 and S2 ). Furthermore, we observed a significant reduction of RV fibrosis in the SuHx-RD group ( Figure 5F ), but this finding was not significant neither in the MCT model ( Figure 5E ) nor in the LV from both models ( Supplemental Tables S1 and S2 ). Figures 6E to 6H) . Recent studies have revealed that both the SNS as well as the RAAS are upregulated and closely associated to disease progression in PH patients (4) .
However, whether RD may be clinically beneficial in PH patients is currently unclear.
Promising beneficial effects of RD have been published recently in a canine model for PH (32, 33) .
In contrast to our study, they initiated treatment before PH development, which limits the clinical translation of their findings. Therefore, we performed a therapeutic study with RD in 2 well-established PH animal models, the MCT and SuHx rat models. We demonstrated that chronic RD treatment delayed disease progression and reduced pulmonary vascular remodeling and proliferation in both animal models.
Previous data from our group revealed that both systemic as well as local RAAS activity is increased in PH patients and closely related to disease progression (4). Specifically, altered expression of the AT1 receptor was identified as a key regulator of increased RAAS in the pulmonary vasculature because its acute and chronic inhibition resulted in marked improvements in pulmonary vascular remodeling and smooth muscle cell proliferation (4) .
Therefore, to investigate whether changes in local RAAS could explain the delayed disease progression and pulmonary vascular remodeling after RD, we assessed AT1 receptor density and cell proliferation in both models. Intriguingly, RD was able to reduce Renal Denervation in Experimental PH Furthermore, experimental studies in hypertensive and chronic pressure overload rat models demonstrated that RD was able to ameliorate LV maladaptive remodeling (37, 38) .
In the current study, we provide evidence that RD improved RV diastolic stiffness and RV remodeling in PH rats. We observed no significant changes in RV relaxation (dP/dt min, Tau), which do not necessarily correlate with RV stiffness (39) .
Recently, we demonstrated that in severe PH, in addition to the myofibril stiffness, fibrosis also contributed to increase RV diastolic stiffness (40 One limitation of our pressure-volume analyses is that we cannot obtain the absolute end-systolic/ -diastolic volumes; therefore, some parameters cannot be estimated (e.g., the pressure-volume loop intercept, V0). However, the reported PV-derived parameters Ees, Eed, and Ea only rely on absolute changes in volumes, and do not depend on absolute volume measurements. Finally, we cannot exclude the possibility that renal denervation may have resulted in a small but clinically relevant increase in RV end-diastolic volume that we were not able to detect by echocardiography.
CONCLUSIONS
Using 2 well-established PH animal models, we provided evidence that chronic RD treatment delayed 
